Anixa Biosciences (NASDAQ:ANIX) Given "Buy" Rating at D. Boral Capital

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

D. Boral Capital reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX - Free Report) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $10.00 target price on the stock.

Separately, Wall Street Zen raised shares of Anixa Biosciences from a "sell" rating to a "hold" rating in a research note on Friday, June 6th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $9.00.

Anixa Biosciences Price Performance

Shares of ANIX stock traded up $0.03 during trading hours on Tuesday, reaching $2.95. The company had a trading volume of 24,786 shares, compared to its average volume of 87,534. Anixa Biosciences has a 1-year low of $2.07 and a 1-year high of $4.20. The firm has a market cap of $95.02 million, a price-to-earnings ratio of -7.76 and a beta of 0.43. The company has a 50 day moving average of $3.23 and a 200 day moving average of $2.98.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last released its quarterly earnings data on Tuesday, June 3rd. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. As a group, sell-side analysts forecast that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Activity

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the business's stock in a transaction dated Thursday, July 31st. The shares were acquired at an average price of $3.08 per share, for a total transaction of $30,800.00. Following the acquisition, the director directly owned 953,334 shares of the company's stock, valued at approximately $2,936,268.72. This trade represents a 1.06% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Amit Kumar bought 10,000 shares of the stock in a transaction that occurred on Wednesday, June 4th. The shares were acquired at an average cost of $2.85 per share, with a total value of $28,500.00. Following the completion of the purchase, the chief executive officer owned 569,925 shares in the company, valued at $1,624,286.25. This represents a 1.79% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 45,000 shares of company stock worth $139,200 in the last quarter. 25.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Anixa Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Millennium Management LLC bought a new stake in Anixa Biosciences in the 4th quarter valued at $26,000. NewEdge Advisors LLC acquired a new stake in shares of Anixa Biosciences in the 2nd quarter valued at about $33,000. Renaissance Technologies LLC raised its stake in shares of Anixa Biosciences by 36.5% in the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock valued at $34,000 after purchasing an additional 3,900 shares during the period. Private Advisor Group LLC bought a new stake in shares of Anixa Biosciences in the first quarter valued at about $35,000. Finally, Benjamin Edwards Inc. acquired a new position in shares of Anixa Biosciences during the second quarter worth about $37,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.